Tomonobu Hasegawa

Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.

Mary Lee, Patricia K. Donahoe, Tomonobu Hasegawa et al. · The Journal of Clinical Endocrinology & Metabolism · 1996 · 410 citations · Full text

Fertility, Reproductive Health, Pathology +20

Gain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome

Yoko Aoki, Tetsuya Niihori, Toshihiro Banjo et al. · The American Journal of Human Genetics · 2013 · 328 citations · Full text

Signal Transduction, Autoimmune Disease, Genetic Disorder +6

SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7

Satoshi Narumi, Naoko Amano, Tomohiro Ishii et al. · Nature Genetics · 2016 · 321 citations

Mendelian Disorder, Genetic Disorder, Mirage Syndrome +9

Developmental Roles of the Steroidogenic Acute Regulatory Protein (StAR) as Revealed by StAR Knockout Mice

Tomonobu Hasegawa, Liping Zhao, Kathleen M. Caron et al. · Molecular Endocrinology · 2000 · 248 citations

Adrenal Gland, Signaling Pathway, Developmental Roles +18

Clinical Assessment and Mutation Analysis of Kallmann Syndrome 1 (<i>KAL1</i>) and Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>, or<i>KAL2</i>) in Five Families and 18 Sporadic Patients

Naoko Sato, Noriyuki Katsumata, Masayo Kagami et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 219 citations · Full text